Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 4/20 | 0.58 |
| ▸ | MAOA | P21397 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11602141 | 0.86 | LTA4H (0.58) | LTA4HSIGMAR1MAOBMAOALMNA | |
| SCHEMBL9636060 | 0.86 | LTA4H (0.58) | LTA4HSIGMAR1MAOBMAOALMNA | |
| SCHEMBL2750286 | 0.86 | LTA4H (0.67) | LTA4HSIGMAR1MAOBMAOASLC6A2 | |
| SCHEMBL9637755 | 0.86 | MAOB (0.59) | LTA4HSIGMAR1MAOBMAOALMNA | |
| SCHEMBL12532788 | 0.86 | LTA4H (0.67) | LTA4HSIGMAR1MAOBMAOASLC6A2 | |
| SCHEMBL2750285 | 0.86 | LTA4H (0.67) | LTA4HSIGMAR1MAOBMAOASLC6A2 | |
| SCHEMBL14491817 | 0.85 | MAOB (0.56) | LTA4HSIGMAR1MAOBPPARAMAPT | |
| Hydrochloric Acid SCHEMBL9021063 | 0.84 | MAOB (0.67) | LTA4HSIGMAR1MAOBMAOASLC6A2 | |
| SCHEMBL12585105 | 0.84 | MAOB (0.61) | MAOBMAOASLC6A2SLC6A3RAB9A | |
| Ammonia Solution, Strong SCHEMBL8865735 | 0.83 | BCHE (0.65) | LTA4HSIGMAR1MAOBMAOALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3400229-B1 | 18/19F-LABELLED COMPOUNDS WHICH TARGET THE PROSTATE SPECIFIC MEMBRANE ANTIGEN | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-03-06 | — | — | EP | disclosed |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | LIEBER INST INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-10934283-B2 | COMT inhibiting methods and compositions | LIEBER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | BRITISH COLUMBIA CANCER AGENCY BRANCH | 2021-01-05 | — | — | US | disclosed |
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-9891239-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2018-02-13 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-7291623-B2 | Compounds that interact with kinases | ALCHEMIA LIMITED (AU) | 2007-11-06 | — | — | US | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| US-7241780-B2 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | BRISTOLS-MYERS SQUIBB COMPANY (US) | 2007-07-10 | — | — | US | disclosed |
| US-7223881-B2 | Process for the preparation of new antidiabetic agents | DR. REDDY'S LABORATORIES LIMITED (IN) | 2007-05-29 | — | — | US | disclosed |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | CHENG PETER T | 2007-01-18 | — | — | US | disclosed |
| EP-0519353-B1 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-08-16 | — | — | EP | disclosed |
| US-5334716-A | Preventing testosteron 5a-reductase mediated diseases; alopecia, acne, prostatism | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-08-02 | — | — | US | disclosed |
| EP-0519353-A2 | Indolizin derivatives, process for their preparation and pharmaceutical composition containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745384-B2 | Indazole derivatives as αv integrin antagonists | ITGB3, ITGB1, ITGAV | LTA4H 547/4885SIGMAR1 1425/4885MAOB 2947/4885 |
| US-10882871-B2 | 18/19F-labelled compounds which target the prostate specific membrane antigen | KLK3, FOLH1, FOLR1 | LTA4H 3355/4885SIGMAR1 4522/4885MAOB 1168/4885 |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | LTA4H 906/4885SIGMAR1 70/4885MAOB 902/4885 |
| US-20210139479-A1 | COMT Inhibiting Methods and Compositions | COMT, PNMT, HNMT | LTA4H 2704/4885SIGMAR1 2412/4885MAOB 5/4885 |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | LTA4H 1980/4885SIGMAR1 796/4885MAOB 2503/4885 |
| US-20230117680-A1 | CYCLOPHILIN D INHIBITORS AND USES THEREOF | PPID, PPIF, PPIL1 | LTA4H 1559/4885SIGMAR1 1594/4885MAOB 838/4885 |
| US-11779663-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | LTA4H 2561/4885SIGMAR1 4842/4885MAOB 2859/4885 |
| US-10934283-B2 | COMT inhibiting methods and compositions | COMT, MAOB, MAOA | LTA4H 3196/4885SIGMAR1 1225/4885MAOB 2/4885 |
| US-20070015797-A1 | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method | GPR119, LIPC, ACACA | LTA4H 3219/4885SIGMAR1 601/4885MAOB 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.